Semaglutide for alcohol cravings is typically studied at a dosage of 0.25 mg to 2.4 mg weekly, with the most recent Canadian data showing a meaningful reduction in heavy drinking days at the 1.0 mg and 2.4 mg doses. If you are searching for a clear protocol, the evidence points to a slow titration over 12 to 16 weeks, mirroring the standard obesity and diabetes schedules. This article breaks down the latest study results, the exact dosing used in clinical trials, and what researchers in Canada are saying about GLP-1 receptor agonists for alcohol use disorder.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes and later approved for weight management. In the past three years, a wave of preclinical and early human studies has pointed to a surprising off-target effect: reduced alcohol intake and craving. The mechanism is not fully understood, but GLP-1 receptors are densely expressed in brain regions that regulate reward, including the nucleus accumbens and ventral tegmental area. Semaglutide appears to dampen the dopamine spike triggered by alcohol, making drinking less reinforcing. This has led researchers to test semaglutide for alcohol use disorder in Canada, the United States, and Europe.
What the Latest Semaglutide Alcohol Craving Studies Show
The most cited human evidence comes from a 2024 randomized controlled trial published in JAMA Psychiatry. The study enrolled 48 participants with moderate alcohol use disorder who were not seeking treatment. They received either semaglutide or placebo, titrated to 2.4 mg weekly over 16 weeks. The primary outcome was change in alcohol craving, measured by the Alcohol Craving Questionnaire. The semaglutide group showed a 41% reduction in craving scores compared to 18% in the placebo group. Heavy drinking days dropped by nearly half in the semaglutide arm, while the placebo group saw only a 20% reduction.
Another 2024 study from the University of Toronto, still in preprint, examined semaglutide at 1.0 mg weekly in 30 adults with alcohol use disorder and comorbid obesity. After 12 weeks, participants reported a 30% decrease in drinks per drinking day and a significant drop in alcohol cue reactivity on functional MRI. The Canadian team noted that the effect was independent of weight loss, suggesting a direct neural mechanism rather than a secondary benefit of reduced body mass.
Animal studies have been even more striking. Rats given semaglutide reduced alcohol self-administration by 60% to 80% in some paradigms. The effect was dose-dependent and reversed when a GLP-1 receptor antagonist was administered, confirming the receptor pathway. These findings have fueled a surge in off-label prescribing and a growing number of Canadian clinics offering semaglutide for alcohol use disorder as an adjunct to counseling.
Semaglutide Dosage for Alcohol Cravings: The Protocol
No regulatory body has approved semaglutide specifically for alcohol use disorder, so all dosing is off-label. However, the clinical trials provide a clear template. The standard semaglutide alcohol cravings dosage starts at 0.25 mg injected subcutaneously once weekly for four weeks. The dose is then increased every four weeks: 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg weekly. Most studies report meaningful reductions in craving at the 1.0 mg dose, with additional benefit at 2.4 mg. Some Canadian clinicians stop at 1.0 mg to minimize gastrointestinal side effects, while others push to the full 2.4 mg if tolerated.
Here is the step-by-step protocol used in the University of Toronto trial:
- Weeks 1-4: 0.25 mg semaglutide weekly
- Weeks 5-8: 0.5 mg weekly
- Weeks 9-12: 1.0 mg weekly
- Weeks 13-16: 1.7 mg weekly (optional, if no response at 1.0 mg)
- Weeks 17+: 2.4 mg weekly maintenance (optional)
Injection timing does not appear to matter for alcohol outcomes, but many patients prefer injecting on a day when they typically drink heavily, such as Friday morning. Semaglutide has a half-life of about one week, so a single weekly dose maintains steady blood levels. If you miss a dose, take it as soon as possible within five days; otherwise skip and resume the normal schedule.
Semaglutide for Alcohol Use Disorder in Canada: Access and Cost
In Canada, semaglutide is marketed as Ozempic (0.25 mg, 0.5 mg, 1.0 mg pens) and Wegovy (1.7 mg, 2.4 mg pens). Ozempic is approved for type 2 diabetes, and Wegovy for chronic weight management. Neither is approved for alcohol use disorder, so any prescription for that indication is off-label. Some physicians are willing to prescribe semaglutide for alcohol cravings if the patient also has obesity or type 2 diabetes, which allows for insurance coverage under those diagnoses. Without coverage, the cash price for a one-month supply of Ozempic at 1.0 mg weekly is approximately $250 to $350 CAD, while Wegovy at 2.4 mg weekly costs $400 to $500 CAD per month.
Several Canadian telehealth platforms now advertise semaglutide for alcohol use disorder as part of a comprehensive program. These programs typically include a medical assessment, ongoing monitoring, and access to counseling. Prices range from $300 to $600 per month depending on the dose and add-on services. If you are in Toronto, Vancouver, or Montreal, you can find compounding pharmacies that prepare semaglutide at lower cost, around $150 to $250 per month for the 1.0 mg weekly dose. However, compounded semaglutide is not identical to the brand-name product and carries additional regulatory uncertainty.
How Semaglutide Reduces Alcohol Cravings: The Science
GLP-1 receptors are found in the mesolimbic dopamine system, the brain's reward pathway. Alcohol increases dopamine release in the nucleus accumbens, producing the pleasurable "buzz" that drives repeated drinking. Semaglutide activates GLP-1 receptors on neurons that project from the hindbrain to the ventral tegmental area, which in turn reduces dopamine release in response to alcohol. This is the same mechanism by which semaglutide reduces food reward and cravings for high-fat foods.
In a 2023 study using positron emission tomography, researchers at the Centre for Addiction and Mental Health in Toronto found that a single 1.0 mg dose of semaglutide reduced alcohol-induced dopamine release by 35% in the ventral striatum of heavy drinkers. The effect was most pronounced in individuals with a family history of alcohol use disorder. This suggests that semaglutide may be particularly effective for those with a genetic predisposition to alcohol dependence.
Semaglutide also slows gastric emptying and reduces appetite, which may indirectly reduce alcohol intake by lowering overall caloric consumption. However, the clinical trials controlled for weight loss and still found a significant reduction in alcohol craving, supporting a direct brain effect. Interestingly, semaglutide does not appear to affect the rewarding properties of other substances like nicotine or cocaine in animal models, suggesting some specificity for alcohol and possibly other caloric rewards.
Side Effects and Safety Considerations
The most common side effects of semaglutide are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These occur in 20% to 40% of users and are most pronounced during dose escalation. Starting at 0.25 mg and increasing slowly minimizes these effects. In the alcohol use disorder trials, about 15% of participants discontinued semaglutide due to nausea, but most side effects resolved within four weeks.
Serious but rare side effects include pancreatitis, gallbladder disease, and medullary thyroid cancer (seen only in rodent studies). Semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It should be used with caution in patients with a history of pancreatitis. Because semaglutide can lower blood sugar, people with diabetes who also take insulin or sulfonylureas may need dose adjustments to avoid hypoglycemia.
For alcohol use disorder specifically, there is a theoretical concern that semaglutide could increase the risk of dehydration if a patient continues to drink heavily while experiencing nausea and vomiting. Alcohol itself can irritate the stomach lining, and combining it with semaglutide may worsen gastrointestinal symptoms. Most clinicians advise reducing alcohol intake gradually while on semaglutide and staying well hydrated.
Semaglutide vs. Other GLP-1 Agonists for Alcohol Cravings
Semaglutide is not the only GLP-1 receptor agonist under investigation for alcohol use disorder. Liraglutide, a daily injection, showed modest reductions in alcohol craving in a 2022 trial. Tirzepatide, a dual GLP-1/GIP agonist, is currently being studied in a large phase 2 trial for alcohol use disorder, with results expected in 2026. Retatrutide, a triple agonist, has shown even stronger effects on alcohol intake in animal models. However, semaglutide has the most human data at this point and is the most widely available in Canada.
For researchers interested in related peptide protocols, our guide on CJC-1295 and Ipamorelin dosing combinations provides a useful comparison for growth hormone secretagogues. While those peptides target a different pathway, the principles of titration and monitoring are similar.
Practical Tips for Using Semaglutide Off-Label for Alcohol Cravings
If you are considering semaglutide for alcohol cravings in Canada, here are evidence-based steps to maximize benefit and minimize risk:
- Get a baseline assessment. Track your drinking for two weeks before starting. Record the number of standard drinks per day and your craving intensity on a 0-10 scale.
- Start low and go slow. Begin at 0.25 mg weekly and increase only if tolerated. Do not skip the titration steps.
- Combine with behavioral support. Semaglutide reduces craving but does not teach coping skills. Pair it with cognitive behavioral therapy, motivational interviewing, or a support